Browse > Article
http://dx.doi.org/10.9721/KJFST.2014.46.4.516

Resveratrol Prevents Hormone-refractory Prostate Cancer Cell Growth via Inhibition of STAT3 Activity  

Cho, Seok-Cheol (Department of Food Science and Engineering, Seowon University)
Choi, Bu Young (Department of Pharmaceutical Science and Engineering, Seowon University)
Publication Information
Korean Journal of Food Science and Technology / v.46, no.4, 2014 , pp. 516-521 More about this Journal
Abstract
The mechanisms underlying the refractory effects of flutamide, a first-line oral anti-androgen drug, have not been entirely elucidated. In the present study, we investigated the mechanism of flutamide-induced hormone-refractory prostate cancer cell growth and its modulation by resveratrol, a phytoalexin present in grapes. Resveratrol significantly attenuated interleukin 6 (IL-6)-induced signal transducer and activator of transcription 3 (STAT3) transcriptional activity and dihydrotestosterone (DHT) or IL-6-induced prostate-specific antigen (PSA) transcriptional activity. Furthermore, compared to treatment with DHT or IL-6 alone, combination treatment of cells significantly increased PSA transcriptional activity, and resveratrol markedly diminished DHT plus IL-6-induced STAT3 and PSA transcriptional activities. Thus, the inhibitory effects of resveratrol on IL-6-, DHT-, and flutamide-induced hormone-refractory prostate cancer cell growth are partly mediated by the suppression of STAT3 reporter gene activity, suggesting that resveratrol represents a promising therapy for prostate cancer.
Keywords
resveratrol; STAT3; IL-6; DHT; hormone-refractory prostate cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 De Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int. 101 (Suppl. 2): 11-15 (2008)
2 Keizman D, Maimon N, Gottfried M. Metastatic hormone refractory prostate cancer: Recent advances in standard treatment paradigm, and future directions. Am. J. Clin. Oncol. 37: 289-296 (2012)
3 Alexandre I, Rixe O. Hormone-refractory prostate cancer. Ann. Urol. (Paris) 41: 47-55 (2007)   DOI
4 Oudard S, Banu E, Scotte F, Beuzeboc P, Guyader C, Medioni J. New targeted therapies in hormone-refractory prostate cancer. Bull. Cancer 94: F62-68 (2007)
5 Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 60: 178-186 (2004)   DOI
6 Bavaresco L. Role of viticultural factors on stilbene concentrations of grapes and wine. Drugs Exp. Clin. Res. 29: 181-187 (2003)
7 Quoc Trung L, Espinoza JL, Takami A, Nakao S. Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One 8: e55183 (2013)   DOI
8 Crawford ED, Rosenblum M, Ziada AM, Lange PH. Hormone refractory prostate cancer. Urology 54: 1-7 (1999)
9 Shakibaei M, Harikumar KB, Aggarwal BB. Resveratrol addiction: to die or not to die. Mol. Nutr. Food Res. 53: 115-128 (2009)   DOI   ScienceOn
10 Tsakalozou E, Eckman AM, Bae Y. Combination effects of docetaxel and doxorubicin in hormone-refractory prostate cancer cells. Biochem. Res. Int. 2012: 832059 (2012)
11 Shinohara N. Bisphosphonate against patients with hormone refractory prostate cancer. Nihon Rinsho Jpn J. Clin. Med. 69 (Suppl. 5): 576-580 (2011)
12 Malhotra M, Dhingra R, Sharma T, Deep A, Narasimhan B, Phogat P, Sharma PC. Cabazitaxel: A novel drug for hormone-refractory prostate cancer. Mini Rev. Med. Chem. 13: 915-920 (2013)   DOI
13 Turitto G, Di Bisceglie M, Moraca L, Sasso N, Sepede C, Suriano A, Romito S. Abiraterone acetate: A novel therapeutic option in hormone-refractory prostate cancer. Recenti Prog. Med. 103: 74-78 (2012)
14 Pitts WR, Jr. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. BJU. Int. 93: 1119-1120 (2004)   DOI
15 Beitzinger M, Hofmann L, Oswald C, Beinoraviciute-Kellner R, Sauer M, Griesmann H, Bretz AC, Burek C, Rosenwald A, Stiewe T. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J. 27: 792-803 (2008)   DOI
16 Sun H, Taneja R. Analysis of transformation and tumorigenicity using mouse embryonic fibroblast cells. Methods Mol Biol. 383: 303-310 (2007)
17 Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer. Curr. Drug Targets 7: 423-442 (2006)   DOI   ScienceOn
18 Hadaschik BA, Gleave ME. Therapeutic options for hormonerefractory prostate cancer in 2007. Urol. Oncol. 25: 413-419 (2007)   DOI